CRISPR-based Gene Editing Market (2026 - 2033)

CRISPR-based Gene Editing Market Summary

The global CRISPR-based gene editing market size was valued at USD 4.5 billion in 2025 and is projected to grow from USD 5.1 billion in 2026 to USD 13.5 billion by 2033, at a CAGR of 14.8% from 2026 to 2033. The market in North America dominated with a revenue share of 41.8% in 2025. This growth is driven by the rising prevalence of genetic disorders, advancements in research and technology, supportive government initiatives, and increasing investment in biotechnology.

Market Dynamics

The CRISPR-based gene editing market is being driven by rapid advances in genome engineering, growing investment in biotechnology research, increasing clinical trial activity for genetic disorders, and expanding applications across therapeutics, agriculture, and industrial biotechnology. Strong funding from venture capital firms, pharmaceutical companies, and government research programs continues to accelerate innovation, while strategic partnerships between biotech firms and large pharmaceutical companies support commercialization efforts. Demand is further influenced by improvements in delivery technologies, rising prevalence of genetic diseases, and increasing interest in personalized medicine, while emerging next-generation editing approaches such as base editing and prime editing are creating new opportunities and intensifying competition within the broader gene-editing landscape.

Market Concentration & Characteristics

The CRIPRS-based gene editing industry is characterized by rapid innovation, driven by ongoing advancements in biotechnology. Recent breakthroughs, such as base editing and prime editing, enhance precision and reduce off-target effects compared to traditional CRISPR methods. For instance, in May 2025, India introduced its first genome-edited rice varieties, DRR Rice 100 (Kamala) and Pusa DST Rice 1, developed using CRISPR-Cas technology by the Indian Council of Agricultural Research (ICAR). These varieties enhance yield, climate resilience, and water-use efficiency, significantly advancing agricultural biotechnology and further supporting expansion in the CRISPR-based genome editing industry.

Mergers and acquisitions (M&A) play a significant role in the CRIPRS-based gene editing industry, as companies seek to consolidate resources and expertise to enhance their competitive edge. For instance, in June 2025, Eli Lilly, the world's most valuable pharmaceutical company, announced the acquisition of gene-editing biotech Verve Therapeutics for up to USD 1.3 billion. This move aimed to bolster Lilly's cardiovascular pipeline. Verve's lead program targets a single-dose CRISPR-based treatment for familial hypercholesterolemia, a genetic condition causing high cholesterol levels. The acquisition reflects Lilly's strategic focus on expanding its gene-editing capabilities in the cardiovascular sector. This strategic consolidation enhances research and development efforts, streamlines regulatory processes, and broadens market reach, ultimately fostering growth in CRISPR applications in medicine.

Regulatory frameworks are critical in shaping the CRISPR-based gene editing industry. Approvals from authorities like the US FDA, European Medicines Agency (EMA), and UK MHRA for therapies such as exa-cel (Casgevy) have validated CRISPR’s clinical potential and increased investor and patient confidence. Clear guidelines for clinical trials, gene therapy manufacturing, and biosafety standards facilitate faster development and commercialization of new therapies. Conversely, stringent ethical oversight and country-specific restrictions on human germline editing or genetically modified organisms (GMOs) can slow adoption and limit market access in certain regions. Overall, a well-defined regulatory landscape encourages responsible innovation, mitigates risks, and is a key enabler for the sustainable growth of the global CRISPR market.

The market is poised for significant expansion, leveraging advanced biotechnologies to enhance gene editing capabilities. Companies can launch novel products to explore new tool varieties, improve genome editing precision, and optimize workflows. For instance, in July 2025, US-based Integrated DNA Technologies (IDT) expanded its CRISPR translational portfolio with high-purity gRNAs, off-target analysis services, and regulatory support, accelerating the development of personalized gene-editing therapies. This strategy meets consumer demand and promotes sustainable growth in the market.

The regional expansion of CRISPR-based gene editing industry is rapidly gaining momentum, particularly in North America, Europe, and the Asia-Pacific. North America, led by the U.S., dominates the market due to its robust R&D infrastructure and substantial funding from both public and private sectors. NIH’s investment in CRISPR research has accelerated the development of novel therapies targeting genetic disorders.

Analyst Perspective

The CRISPR-based gene editing market is transitioning from a primarily research-driven space into a clinically and commercially oriented ecosystem, supported by accelerating therapeutic approvals and a maturing clinical pipeline. While early momentum is strongly driven by breakthroughs in treating rare genetic disorders, the next phase of growth will depend on scalability, delivery efficiency, and long-term safety validation across broader disease indications. Competitive intensity is increasing as established biotech firms, pharmaceutical companies, and emerging startups pursue differentiated CRISPR platforms, including next-generation editing tools. However, investors and stakeholders remain cautious due to regulatory complexity, ethical scrutiny, and reimbursement uncertainty. Overall, the market is expected to evolve into a highly specialized but high-value segment within advanced therapeutics, where success will be defined by clinical efficacy, manufacturing scalability, and strategic partnerships.

Advancements in CRISPR Technology & Applications

Advancements in CRISPR technology and applications are significantly accelerating market growth by enhancing precision, efficiency, and versatility in gene editing. Since its discovery, the CRISPR-Cas system has evolved beyond basic DNA cutting into a sophisticated genome engineering platform. It is supported by innovations such as high-fidelity Cas variants, base editing, prime editing, and improved delivery mechanisms such as lipid nanoparticles and viral vectors. These improvements have reduced off-target effects, increased editing efficiency, and broadened the scope of treatable conditions. Integration with artificial intelligence (AI) and machine learning has further optimized guide RNA design and target site selection, enabling faster, more accurate development cycles. Technology’s adaptability also supports multiplexed editing, allowing simultaneous modification of multiple genes crucial for tackling complex diseases and traits.

Key CRISPR Mechanisms, Applications, And Examples

Source: ScienceDirect, Secondary Research, Grand View Research

These advancements also expand CRISPR into new application areas beyond human therapeutics, including agriculture, industrial biotechnology, diagnostics, and environmental management. In agriculture, CRISPR is being applied to create climate-resilient, pest-resistant, and nutrient-enhanced crops, offering solutions to food security challenges. In diagnostics, CRISPR-based tools such as SHERLOCK and FELUDA enable rapid, low-cost detection of infectious diseases. At the same time, in synthetic biology, CRISPR is used to engineer microorganisms for sustainable biofuel and material production. The widening scope of CRISPR applications, coupled with ongoing technical refinements, is attracting strong investments from pharmaceutical companies, agri-biotech firms, and research institutions. This continual innovation cycle expands the addressable market and strengthens CRISPR’s position as a transformative technology platform across multiple industries.

Increasing Prevalence of Genetic Disorders

The growing prevalence of genetic disorders is a key catalyst for the CRISPR-based gene editing market. According to the World Health Organization (WHO), around 6% of newborns globally are affected by serious genetic congenital disabilities, representing millions of new cases each year. Conditions such as sickle cell disease, beta-thalassemia, cystic fibrosis, Duchenne muscular dystrophy, Huntington's disease, and hemophilia contribute to substantial clinical and economic burdens worldwide. Advances in genetic screening, increased awareness, and improved diagnostics are revealing a larger patient pool, while demographic shifts such as higher parental age further increase the risk of hereditary conditions. In addition, improved survival rates of infants with complex medical needs mean more individuals live with these disorders into adulthood, expanding the long-term patient base.

Conventional therapies for genetic disorders are often symptom-focused and lifelong, offering limited impact on disease progression. This gap fuels interest in curative approaches such as CRISPR-based gene editing, which enables targeted correction of disease-causing mutations at the DNA level. Breakthrough approvals, such as exa-cel (Casgevy) for sickle cell disease and beta-thalassemia, have validated the clinical potential of these technologies and boosted confidence among healthcare providers, patients, and investors. As genetic testing adoption rises and precision medicine becomes mainstream, the demand for advanced gene editing solutions is set to accelerate, positioning CRISPR as a cornerstone in the treatment landscape for inherited diseases.

Product & Service Insights

Based on product & services, the product segment led the market with the largest revenue share of 73.5% in 2025. The widespread adoption of CRISPR technology in research laboratories has led to a significant demand for high-quality enzymes and kits essential for gene editing applications. Moreover, CRISPR libraries, which allow researchers to conduct high-throughput screenings and facilitate functional genomics studies, are gaining traction. These libraries are pivotal for drug discovery and developing novel therapies, addressing critical health challenges such as cancer and genetic disorders.

The services segment is expected to witness the fastest CAGR over the forecast period. As CRISPR technology becomes increasingly mainstream, researchers and organizations require specialized services for effective implementation, including designing, optimizing, and validating CRISPR systems. GenScript and Integrated DNA Technologies have introduced comprehensive service packages that include gene synthesis, cell line development, and custom CRISPR libraries. These offerings simplify the research process and accelerate project timelines, making them attractive to researchers under pressure to deliver results quickly. Moreover, as educational initiatives and workshops on CRISPR technology proliferate, more researchers seek expert services to enhance their understanding and application of this powerful tool. This growing demand will propel the services segment to new heights.

Application Insights

Based on application, the biomedical segment led the market with the largest revenue share of 82.2% in 2025. This growth is fueled by several key drivers, including the increasing prevalence of genetic disorders and cancers, alongside significant advancements in CRISPR technology. CRISPR technology's ability to precisely edit genes offers transformative potential for conditions such as sickle cell disease and Duchenne muscular dystrophy, driving research and investment in this area. CRISPR's application in developing targeted therapies has garnered attention in oncology, with clinical trials underway for various cancers showcasing promising results in altering tumor genetics. For instance, in December 2024, USC biomedical engineers in the US developed a focused ultrasound-controlled CRISPR toolkit, enabling precise, remote-activated genome editing and enhancing cancer immunotherapy efficacy in preclinical mouse models.

The agricultural segment is expected to witness significant growth over the forecast period, driven by CRISPR’s ability to deliver precise, cost-effective genetic modifications that enhance crop yield, nutritional value, and resistance to pests, diseases, and environmental stressors. Compared to conventional breeding and transgenic methods, CRISPR offers faster development timelines and greater regulatory acceptance in certain markets, making it highly attractive to agri-biotech companies. Applications include engineering drought-tolerant cereals, disease-resistant fruits, and biofortified staples to address global food security challenges. Moreover, CRISPR is being used to improve livestock traits, such as disease resistance and productivity, further broadening its agricultural utility. As climate change intensifies and demand for sustainable farming practices rises, adoption of CRISPR in agriculture is expected to accelerate, supported by growing R&D investment and public-private partnerships worldwide.

End Use Insights

Based on end use, the pharmaceutical & biotechnology companies segment led the market with the largest revenue share of 46.1% in 2025. Pharmaceutical and biotechnology companies are at the forefront of addressing a range of genetic disorders and complex diseases, such as sickle cell anemia, cystic fibrosis, and various cancers, by leveraging CRISPR technology to develop targeted therapies. Recent industry developments further underscore the growth potential of this segment. Numerous biotech firms are actively conducting clinical trials employing CRISPR technology, with regulatory agencies increasingly supporting these initiatives. This trend reflects growing confidence in the safety and efficacy of CRISPR applications. For instance, in May 2023, Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced a new non-exclusive licensing agreement. This collaboration focuses on utilizing CRISPR Therapeutics’ CRISPR/Cas9 gene editing technology to expedite the development of Vertex’s hypoimmune cell therapies for type 1 diabetes, showcasing the practical applications and transformative potential of CRISPR in treating chronic conditions.

The contract research organizations segment is projected to witness the fastest CAGR over the forecast period. This growth is driven by the increasing complexity of research and development in biotechnology, alongside a rising demand for specialized expertise in gene editing. CROs play a crucial role by providing essential services such as assay development, regulatory compliance, and clinical trial management. This enables pharmaceutical and biotech companies to concentrate on their core competencies while ensuring timely and budget-conscious project completion.

Regional Insights

North America dominated the CRISPR-based gene editing market with the largest revenue share of 41.8% in 2025. This leadership is largely attributed to the strong presence of major biotechnology and pharmaceutical companies and substantial investments in research and development. The region also benefits from supportive regulatory frameworks that facilitate innovation and accelerate the approval process for new therapies. Moreover, the high prevalence of genetic disorders, which affects millions of individuals in the U.S., highlights the urgent demand for effective treatments.

U.S. CRISPR-based Gene Editing Market Trends

The CRISPR-based gene editing market in the U.S. held the largest share in the North America region in 2025. The CRISPR-based gene editing industry in the U.S. is anticipated to experience a significant CAGR during the forecast period, due to rising investments in biotechnology and healthcare innovation. The regulatory environment is becoming more conducive, with the FDA providing clearer guidelines for gene editing therapies. Recent collaborations between academic institutions and biotech firms are accelerating the development of CRISPR applications, particularly in oncology and rare genetic disorders. Moreover, numerous government initiatives aim to bolster biotechnology research. For instance, the U.S. government has invested heavily in the "Precision Medicine Initiative," which seeks to tailor treatments to individual genetic profiles.

Europe CRISPR-based Gene Editing Market Trends

The CRISPR-based gene editing market in Europe is anticipated to grow significantly over the forecast period, driven by strong governmental support and a collaborative research environment. European countries are investing heavily in biotechnology research, with initiatives like Horizon Europe, which allocates substantial funding to genetic research. Regulatory agencies, such as the European Medicines Agency, are also becoming more proactive in facilitating the approval of gene editing therapies, enhancing the market's growth prospects.

CRISPR-based gene editing industry in UK is expected to witness a significant CAGR during the forecast period, fueled by strong government support for genomic research, a robust biotechnology ecosystem, and early regulatory approvals. The country’s advanced clinical research infrastructure, active academic-industry collaborations, and investment in precision medicine initiatives are accelerating the translation of CRISPR innovations from lab to market. Moreover, the UK’s focus on therapeutic and agricultural applications and a favorable IP environment positions it as a key growth hub in the global CRISPR landscape.

Germany CRISPR-based gene editing market is expected to grow at a substantial CAGR over the forecast period, driven by the country’s strong biomedical research infrastructure, significant public and private R&D investments, and leadership in precision medicine initiatives. Germany’s well-established pharmaceutical and biotechnology sectors, supported by leading academic institutions and research clusters such as the Max Planck Society and Helmholtz Association, foster innovation in CRISPR applications for therapeutics, agriculture, and industrial biotechnology. Moreover, favorable government funding programs, participation in EU-wide genomic projects, and a focus on ethical yet progressive regulatory policies create an enabling environment for market expansion.

Asia Pacific CRISPR-based Gene Editing Market Trends

The CRISPR-based gene editing market in the Asia Pacific is anticipated to witness the fastest CAGR of 15.7% throughout the forecast period, driven by expanding biotechnology and pharmaceutical sectors, rising healthcare expenditure, and increasing adoption of precision medicine. Countries such as China, Japan, South Korea, and India invest heavily in genomic research, clinical trials, and CRISPR-based product development, supported by government initiatives and favorable policy reforms. For instance, in January 2025, India’s CrisprBits opened a Bengaluru gene editing and diagnostics centre, enhancing CRISPR R&D capacity and advancing affordable rare disease, antimicrobial resistance, and hospital-acquired infection diagnostics. The region also benefits from a large patient population with unmet medical needs, accelerating demand for advanced genetic therapies. Collaborative efforts between academic institutions, biotech startups, and multinational companies will strengthen the Asia Pacific’s position as a high-growth hub in the global CRISPR landscape.

China CRISPR-based gene editing market is expected to grow significantly over the forecast period, driven by substantial government investment in life sciences and biotechnology. China’s growing healthcare needs, fueled by a rising population and increasing incidence of genetic disorders, necessitate innovative solutions. The Chinese government has implemented favorable policies to encourage research and development in gene editing, resulting in numerous clinical trials and collaborations between research institutions and biotech firms.

CRISPR-based gene editing market in Japan is set for strong growth, driven by advanced life sciences infrastructure, substantial government funding, and active international collaborations. Applications span rare disease therapeutics, regenerative medicine, and agriculture, supported by a clear regulatory framework and rising demand for precision medicine amid an aging population. For instance, in July 2025, Japan’s Mie University used CRISPR-Cas9 to remove the extra chromosome 21 in Down syndrome cells, marking a milestone in chromosome-level editing with potential therapeutic applications.

MEA CRISPR-based Gene Editing Market Trends

The CRISPR-based gene editing market in the Middle East and Africa is poised for substantial growth during the forecast period, fueled by rising investments in healthcare infrastructure and biotechnology research. Governments and private entities increasingly recognize the importance of genetic research in addressing regional health challenges, driving greater funding and collaborations between research institutions and biotech companies. The region’s high prevalence of genetic disorders, most notably sickle cell disease (SCD), identified by the World Health Organization (WHO) as the most common genetic disorder in Africa, highlights the urgent need for advanced therapeutic solutions. This combination of unmet medical needs, expanding research capacity, and growing demand for innovative healthcare technologies is expected to accelerate CRISPR adoption across the region.

The CRISPR-based gene editing industry in Kuwait is poised for growth, driven by increasing government investment in healthcare innovation, expanding biotechnology research capabilities, and rising adoption of precision medicine. The country’s focus on diversifying its economy through science and technology initiatives and partnerships between local institutions and global biotech companies fosters a supportive ecosystem for CRISPR applications.

Key CRISPR-based Gene Editing Company Insights

The CRISPR-based gene editing market is characterized by several established players who maintain dominance through advanced technology platforms, strategic partnerships, and sustained investment in research and development. Industry leaders such as Revvity, Inc., Danaher, GenScript, Merck KGaA, and Thermo Fisher Scientific, Inc. have secured significant market share by offering robust CRISPR toolkits, broad application coverage, and strong global distribution networks. These companies continue to advance the field through innovations in high-fidelity Cas variants, precision delivery systems, and scalable manufacturing solutions catering to research and clinical applications.

Other key participants, including Tocris Bioscience, OriGene Technologies, Inc., Bio-Rad Laboratories, Bio-Techne, and New England Biolabs, Inc., are expanding their footprint by providing specialized reagents, assay systems, and customized gene editing services tailored to the evolving needs of academic institutions, pharmaceutical companies, and agricultural biotechnology enterprises. These organizations leverage their technical expertise to address the growing demand for reliable, efficient, and application-specific CRISPR solutions across therapeutic, diagnostic, and industrial domains.

Leading players in this market have solidified their positions by integrating cutting-edge CRISPR technologies with comprehensive service portfolios and global outreach. As the demand for precision medicine, regenerative therapies, agricultural genome improvement, and synthetic biology accelerates, the market landscape will be increasingly shaped by a commitment to scalability, accessibility, and regulatory compliance. These factors will be critical in aligning CRISPR innovation with broader healthcare, food security, and sustainability objectives.

The CRISPR-based gene editing industry is witnessing a dynamic interplay between established expertise and emerging innovators. Mergers, acquisitions, strategic alliances, and continual improvements in editing accuracy, delivery efficiency, and safety profiles fuel intense competition. Companies that can successfully merge scientific breakthroughs with customer-focused solutions and ethical considerations are best positioned to capture sustained value and drive the future trajectory of this transformative sector.

Key CRISPR-based Gene Editing Companies

The following key companies have been profiled for this study on the CRISPR-based gene editing market.

• Revvity, Inc.

• Danaher

• GenScript

• Merck KGaA

• Thermo Fisher Scientific, Inc.

• Tocris Bioscience

• OriGene Technologies, Inc.

• Bio-Rad Laboratories

• Bio-Techne

• New England Biolabs, Inc.

Competitive Benchmarking

Recent Developments

• In May 2025, Danaher used its Business System to deliver the world’s first mRNA-based personalized CRISPR therapy in under six months, accelerating treatment for a child with neonatal-onset CPS1 deficiency.

• In April 2025, Kytopen and Aldevron partnered to integrate Nanoplasmid and Flowfect Tx technologies, enhancing CRISPR-mediated T-cell engineering, boosting yields, and streamlining GMP manufacturing for advanced cell therapy applications.

CRISPR-based Gene Editing Market Report Scope

Global CRISPR-based Gene Editing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global CRISPR-based gene editing market based on product & service, application, end use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)

  • Products

    • CRISPR Kits & Reagents

    • CRISPR Libraries

    • Others

  • Services

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Biomedical

    • Therapeutic Development

      • By Indication

        • Genetic Disorders

        • Oncology

        • Ophthalmology

        • Others

      • By Delivery Method

        • Ex Vivo

        • In Vivo

    • Disease Diagnostics

  • Agricultural applications

    • Plant Engineering

    • Farm Animals Engineering

    • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes

  • Contract Research Organizations

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations